Borderline Personality Disorder Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Effectiveness of a Short and Telematic Version of Cognitive-behavioral Treatment for Borderline Personality Disorder
Condition: Borderline Personality Disorder Interventions: Behavioral: Dialectical Behavior Therapy -3-months; Behavioral: Dialectical Behavior Therapy -6-months Sponsors: Pontificia Universidad Catolica de Chile; University Diego Portales Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2021 Category: Research Source Type: clinical trials
ORYZON Enrolls First Patient in PORTICO, a Phase IIb Clinical Trial with Vafidemstat in Borderline Personality Disorder
MADRID, SPAIN and CAMBRIDGE, MA, UNITED STATES, March 29th, 2021 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 29, 2021 Category: Pharmaceuticals Source Type: clinical trials
